Company intelligence / Profile preview

Bradmer Pharmaceuticals Inc.

Toronto, Ontario, Canadadnb.com ↗

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Bradmer initiated a Phase III GLASS-ART Trial for Neuradiab in glioblastoma multiforme, but faced logistical issues with site initiation and patient enrollment. Prior Phase I and Phase II trials showed survival benefits exceeding historical controls. As of 2009, the company was evaluating strategic alternatives due to projected delays in patient enrollment.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodiesRadioimmunotherapy
Industry: Biotech

Drug pipeline

1 asset

tenascin antibody

Unknown

Partnerships

Duke University Medical Center

Beyond the preview

Go deeper on Bradmer Pharmaceuticals Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bradmer Pharmaceuticals Inc..

Explore the full profile